Patents by Inventor Oliver Boris Stauch

Oliver Boris Stauch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210054092
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10752696
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 25, 2020
    Assignee: GENENTECH, INC.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20200079857
    Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
    Type: Application
    Filed: April 22, 2019
    Publication date: March 12, 2020
    Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
  • Publication number: 20190367629
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 5, 2019
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10377831
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10280227
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20180228895
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 9968676
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 15, 2018
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20160166689
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 9345661
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20160137742
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: November 18, 2015
    Publication date: May 19, 2016
    Applicant: GENENTECH, INC.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20160090419
    Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
  • Publication number: 20150086537
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20140093512
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20140005367
    Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toshiyuki MORICHIKA, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
  • Publication number: 20130296807
    Abstract: A device for automatically delivering a drug to a user and method thereof are disclosed. The device (10, 20, 70, 110) provides a connector to which a vial (12, 50, 60, 100, 130, 202) containing the drug is removably connected and situated thereto in a substantially inverted position. When commanded by the user, the device (10, 20, 70, 110) starts a reconstitution process to automatically create a reconstituted drug, and provides an indication that the reconstitution process is complete such that the vial (12, 50, 60, 100, 130, 202) may be removed from the connector (22, 72,112). After disposing the device (10, 20, 70, 110) on the user, the device (10, 20, 70, 110) can automatically deliver the reconstituted drug to the user when further commanded by the user.
    Type: Application
    Filed: August 10, 2010
    Publication date: November 7, 2013
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Richard Lintern, Edward Murray, Oliver Shergold, Oliver Boris Stauch
  • Patent number: 8568720
    Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
    Type: Grant
    Filed: December 26, 2008
    Date of Patent: October 29, 2013
    Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann - La Roche AG
    Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
  • Publication number: 20120321638
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: July 30, 2012
    Publication date: December 20, 2012
    Inventors: Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20110076273
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 31, 2011
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20110044977
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: July 27, 2010
    Publication date: February 24, 2011
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch